hrp0092p3-203 | Pituitary, Neuroendocrinology and Puberty | ESPE2019

Anapylaxis Secondary to Gonadotrophin Releasing Hormone Agonist used for Precocious Puberty, Two Case Reports

Al Shaikh Hala

Gonadotrophin Releasing Hormone agonists (GnRHa) are used in the management of true precocious and early onset puberty. They have been associated rarely with severe adverse effects such as slipped capital femoral epiphysis, sterile abscess formationand anaphylaxis. Anaphylactic reactions had been reported at a low incidence rate. They can occur early or late after starting treatment or be recurrent after an injection due to the analogue's long half-life.The allergic reacti...

hrp0094p2-91 | Bone, growth plate and mineral metabolism | ESPE2021

Two-year experience of burosumab therapy in pediatric XLH patients in Saudi Arabia

AlJuraibah Fahad , Aldubayee Mohamed , Alsagheer Afaf , Shaikh Adnan Al ,

Background: X-linked hypophosphatemia (XLH) is a rare, often debilitating genetic disorder caused by mutations in the phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PHEX) that is characterized by excess fibroblast growth factor 23 (FGF23), hypophosphatemia, skeletal deformities, and growth impairment.1,2 Conventional therapy with the combination of phosphate and active vitamin D is associated with poor treatment adh...

hrp0082p3-d3-752 | Diabetes (4) | ESPE2014

The Psychological Impact of Diabetes on Glycaemic Control in Affected Saudi Children at Different Developmental Age Groups

Babiker Amir , El Rashid Mona , Al Jurayyan Nasir , Druce Maralyn , Bahebri Aban , El Ahmedi Mohamed , Errasoul Ahmed H , Gasim Hala , Coppack Simon

Background: Diabetes is the third commonest chronic disease of childhood. When a child or an adolescent is diagnosed with type 1 diabetes (T1D), adaptation to a new life is usually a challenge for the whole family. There are specific challenges posed by T1D on the affected children, and their families, at different developmental age groups. The correlation between HbA1c and age specific psychological challenges, to our knowledge, has not been previously explored in the Middle ...

hrp0097p1-196 | Thyroid | ESPE2023

Clinical Pattern and management attitudes of Paediatric Graves' Disease in Saudi Arabia, A 10-Year Experience

Mulla Jaazeel , Al Shaikh Adnan , Aldubayee Mohammad , AlNoaim Khalid , Hakim S , Babiker Amir

Introduction: Graves’ disease (GD) is a leading cause of hyperthyroidism in all age groups. Clinical presentation, methods and overall goals of therapy can be variable in different age groups. We aimed to study the prevalence of GD, the attitude of treating physicians towards management preferences as well as patient response pattern amongst children and adolescents with GD in Saudi Arabia.Methods: A cross sectiona...

hrp0084p3-983 | GH & IGF | ESPE2015

GH Therapy in Kuwait: First Report on Characteristics and Response in Treated Children

Al-Abdulrazzaq Dalia , Al-Basari Iman

Background: Recombinant GH (rGH) treatment is approved in many countries for treatment of short stature in a number of childhood diagnoses. rGH was first introduced in Kuwait in the 1990s. Since its introduction, there has been no reported data on the clinical profile of treated children. There is a huge gap in knowledge of use and response to Paediatric rGH therapy in Kuwait and the region.Objective and hypotheses: The objective of this study is to repo...

hrp0094p2-271 | Growth hormone and IGFs | ESPE2021

Linear growth of prepubertal children born small for gestational age on growth hormone therapy for 3 years

Al Shaikh Adnan , Daftardar Hadeer , Aziz Alghamdi Abdul , Jamjoom Majd , Awidah Saniah , Ahmed Mohamed E , Soliman Ashraf ,

Introduction: Recombinant growth hormone (GH) is an effective treatment for short children who are born small for gestational age (SGA). Short children born SGA who fail to demonstrate catch-up growth by 2-4 years of age are candidates for GH treatment initiated to achieve catch-up growth to a normal height in early childhood, maintain a normal height gain throughout childhood, and achieve an adult height within the normal target range. However, some children ...

hrp0095rfc1.6 | Thyroid | ESPE2022

Frequency and risk factors of hypothyroidism following cardiac catheter in infants with congenital heart diseases: A prospective study

Elbaz Boshra , Elmarsafawy Hala , Laimon Wafaa

Background: This study aims to determine the incidence, clinical course and risk factors of hypothyroidism following cardiac catheter (CC) in infants with congenital heart diseases (CHD).Subjects and Methods: This prospective study included 102 patients with CHD, aged ≤ 3 years who underwent CC. Thyroid function tests were evaluated before CC, one day, one week, two weeks and four weeks after the procedure.<p clas...

hrp0082p3-d2-746 | Diabetes (3) | ESPE2014

Current Status of Diabetes Management, Glycemic Control and Complications in Children and Adolescents with Diabetes: a Registry-Based Study in Egypt: Where Do We Stand Now? and Where Do We Go from Here?

Elbarbary Nancy , Elsamahy Mona , Elmorsi Hala

Background: Given that diabetes is an extremely common disorder in Egypt, the Diabetes Registry was designed by Pediatric Diabetes Clinic, Ain Shams University Hospital in the year 2010.Aim: Identify risk factors related to poor glycemic control and to provide data to health professionals for use in planning, evaluation, and optimizing diabetes care in those patients.Subjects and methods: The registry was designed to provide inform...

hrp0094p2-61 | Bone, growth plate and mineral metabolism | ESPE2021

Experience of 6-months of burosumab therapy in five siblings with X-linked hypophosphataemic rickets in the State of Kuwait

Shammari Sameer Al , Enezi Ayed Al , Sameer George , Fawzy Nagla ,

Background: X-linked hypophosphataemic rickets (XLH) is a genetic disorder, characterized by hypophosphatemia and caused by a mutation in the phosphate regulating endopeptidase homolog, X-linked (PHEX) gene which leads to overexpression of fibroblast growth factor 23 (FGF23).1,2 Conventional therapy, supplementation with oral phosphate and vitamin D analogs, does not treat the underlying cause of the disorder and is associated with poor treatment ad...

hrp0095p1-383 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2022

Study of Quality of Life among Children with Congenital Adrenal Hyperplasia at Alexandria University Children’s Hospital

Elsayed Shaymaa , Gharib Bayoumi , Beshir Hala , Saeed Marwa

Introduction: Quality of life (QoL) is a complex concept with multiple aspects as cognitive and emotional functioning; psychological well-being; general health; physical functioning; and social well-being and functioning. Stressors that appear with cases of Congenital adrenal Hyperplasia (CAH) vary and can present challenges to shared decision making with healthcare providers. Day-to-day care of a chronically ill child affects family finances and dynamics, as ...